Novartis

Novartis Topic Hubs AI drug discovery: News, analysis and interviews Antibody-drug conjugates: The next wave of targeted cancer drugs Biopharma M&A and dealmaking: Who’s buying and why Biopharma people moves: CEO changes, executive hires, board positions Biotech IPOs: Tracking the market for new public offerings Biotech venture funding: Who’s raising and where the money is going Cell and gene therapy manufacturing: Scaling the next frontier China biotech: Licensing deals and the Biosecure Act CRISPR and gene editing: The push for in vivo therapies Drug pricing and the IRA: Tracking the government's negotiation power FDA policy and drug approvals: What’s changing…

Elizabeth Cairns · 2026-09-01

Novartis’ BTK inhibitor Rhapsido has a chance of expanding from a chronic itch treatment to the multiple sclerosis market following wins in two identical Phase 3 trials. The pill significantly cut annualized relapse rates (ARR) ...

Source: Endpoints News